This review covers 11 new therapeutic agents approved in the United States in 2015: sacubitril/valsartan, alirocumab, evolocumab, sonidegib, rolapitant, trifluridine/tipiracil, daratumumab, ixazomib, elotuzumab, daclatasvir, and uridine triacetate. Indications and information on dosage and administration for these agents are reviewed, as are the most important pharmacokinetic properties, drug interactions, efficacy and safety, and other precautions. Practical considerations for the use of these new agents also are discussed. Whenever possible, the properties of the new drugs are compared with those of the older agents marketed for the same indications.
After participating in this activity, the pharmacist will be able to:
- List new therapeutic agents approved by FDA and first marketed during 2015.
- Describe the mechanisms of action and indications for these new therapeutic agents.
- Compare and contrast the new therapeutic agents with products available with similar indications.
- Summarize adverse effects and patient safety considerations for the new therapeutic agents.
- Discuss important patient education and therapeutic monitoring parameters for the new therapeutic agents.
Activity type: Knowledge-based
Learning Level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
To obtain 2.0 contact hours of continuing pharmacy education credit (0.2 CEUs) for completing "New therapeutic agents marketed in 2015: Part 3," complete the CPE examination and evaluation questions. Credit will be awarded upon achieving a passing grade of 70% or better. Please visit CPE Monitor for your statement of credit/transcript.
this continuing pharmacy education examination. Please note that you will not be permitted to submit the examination a third time. Exam questions may not appear in the same order as printed.
The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the test. Individuals completing this activity by March 1, 2019 can receive credit.
Initial release date: March 1, 2016
Expiration date: March 1, 2019
ACPE Universal Activity Number: 0202-0000-16-102-H01-P
Mark S. Johnson, PharmD, BCPS
Professor and Vice Chair, Department of Pharmacy Practice
Director, Postgraduate Education
Bernard J. Dunn School of Pharmacy
Mark S. Johnson, PharmD, BCPS, declares that he and his spouse hold stock in Merck & Co.
Amy M. Lugo, PharmD, BCPS, BC-ADM, FAPhA, and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures please see the APhA Accreditation Information section at www.pharmacist.com/education.
Department of Defense (DoD) disclaimer: The information discussed here represents the views of the author and does not necessarily reflect the views of DoD or the Departments of the Army, Navy, or Air Force.
"New therapeutic agents marketed in 2015: Part 3” is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.
There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-16-102-H01-P||0.2 CEUs||March 01, 2016 - March 01, 2019|